COSCIENS Biopharma Inc T.AEZS

Important news on inflammation and cardiovascular disease

[prophetoffactz]

@EricTopol

 

The Big Miss in Cardiovascular Disease

Not diagnosing or getting on top of arterial inflammation in the new Ground Truths (link in my profile)

Yes, the graph below shows a ~30-fold risk of cardiac death for 3-vessel inflammation, 13-fold for one artery, during extended follow-up

[prophetoffactz]

Where to Go From Here The totality of these findings highlight the importance of systemic and arterial inflammation for risk of major adverse cardiovascular events. We should be using biomarkers, such as hs-CRP, and building on that with better ones that provide an index for body-wide inflammation. We have a cheap drug that has proven efficacy in 6 randomized trials—colchicine. It’s

[prophetoffactz]

The Dr. at the Montreal Heart Institute in charge of AEZS's avenanthramide pill clinical trial, Dr. Jean-Claude Tardif, has run clinical trials on colchicine which is the first FDA approved drug to treat inflammation and heart disease. As noted in the posted article below it has significant side-effects. It can also kill in high enough doses. AEZS is about to present single ascending dose data

[prophetoffactz]

Yes, the graph below shows a ~30-fold risk of cardiac death for 3-vessel inflammation, 13-fold for one artery, during extended follow-up